CR20130020A - Un nuevo conjugado de granulocito colonia-estimiulante factor (g-csf) con polietileno glicol - Google Patents

Un nuevo conjugado de granulocito colonia-estimiulante factor (g-csf) con polietileno glicol

Info

Publication number
CR20130020A
CR20130020A CR20130020A CR20130020A CR20130020A CR 20130020 A CR20130020 A CR 20130020A CR 20130020 A CR20130020 A CR 20130020A CR 20130020 A CR20130020 A CR 20130020A CR 20130020 A CR20130020 A CR 20130020A
Authority
CR
Costa Rica
Prior art keywords
csf
stimulating factor
new
granulocit
colonia
Prior art date
Application number
CR20130020A
Other languages
English (en)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Dmitriy Valentinovich Morozov
Elena Georgievna Rudenko
Elena Leonidovna Morosova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130020(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of CR20130020A publication Critical patent/CR20130020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a farmacéuticos y medicina, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G-CSF).
CR20130020A 2010-08-13 2013-01-18 Un nuevo conjugado de granulocito colonia-estimiulante factor (g-csf) con polietileno glicol CR20130020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (ru) 2010-08-13 2010-08-13 Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе

Publications (1)

Publication Number Publication Date
CR20130020A true CR20130020A (es) 2013-02-20

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130020A CR20130020A (es) 2010-08-13 2013-01-18 Un nuevo conjugado de granulocito colonia-estimiulante factor (g-csf) con polietileno glicol

Country Status (17)

Country Link
KR (1) KR101549457B1 (es)
CN (1) CN103140499B (es)
CL (1) CL2013000400A1 (es)
CO (1) CO6670557A2 (es)
CR (1) CR20130020A (es)
CU (1) CU24139B1 (es)
DO (1) DOP2013000003A (es)
EA (1) EA019043B1 (es)
EC (1) ECSP13012399A (es)
MA (1) MA34525B1 (es)
MY (1) MY160732A (es)
NI (1) NI201300007A (es)
PE (1) PE20131085A1 (es)
RS (1) RS20130094A1 (es)
RU (1) RU2446173C1 (es)
SG (1) SG187572A1 (es)
WO (1) WO2012021088A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
NZ702415A (en) 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (zh) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 一种聚乙二醇修饰的rhG-CSF注射液及其制备方法
RU2535002C2 (ru) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием
RU2016136833A (ru) 2014-02-18 2018-03-22 Чилдрен'З Хоспитал Лос Анджелес Композиции и способы для лечения нейтропении
AU2015291123C1 (en) 2014-07-14 2020-12-10 Gennova Biopharmaceuticals Limited A novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Polypeptides derived from CSF-m and their uses
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
BR112022018501A2 (pt) * 2020-03-17 2022-10-25 Drugrecure Aps Formulação líquida de gm-csf para inalação

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (ko) * 2003-03-21 2004-10-01 한미약품 주식회사 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법
RU2278870C2 (ru) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Способ получения, выделения, очистки и стабилизации рекомбинантного гранулоцитарного колониестимулирующего фактора человека, пригодного для медицинского применения, и иммунобиологическое средство на его основе
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases

Also Published As

Publication number Publication date
WO2012021088A1 (en) 2012-02-16
CO6670557A2 (es) 2013-05-15
PE20131085A1 (es) 2013-10-10
SG187572A1 (en) 2013-03-28
CU24139B1 (es) 2015-12-23
EA201101035A1 (ru) 2012-02-28
CN103140499A (zh) 2013-06-05
NI201300007A (es) 2014-05-26
KR101549457B1 (ko) 2015-09-02
MY160732A (en) 2017-03-15
CN103140499B (zh) 2014-12-17
MA34525B1 (fr) 2013-09-02
ECSP13012399A (es) 2013-05-31
CU20130012A7 (es) 2013-04-19
DOP2013000003A (es) 2013-07-31
RU2446173C1 (ru) 2012-03-27
EA019043B1 (ru) 2013-12-30
RS20130094A1 (en) 2013-08-30
KR20130043167A (ko) 2013-04-29
CL2013000400A1 (es) 2013-07-26

Similar Documents

Publication Publication Date Title
CR20130020A (es) Un nuevo conjugado de granulocito colonia-estimiulante factor (g-csf) con polietileno glicol
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
GB201106750D0 (en) Novel compounds
IL244858A (en) Fumart and Molecular Molecular Couplings, Pharmaceutical Preparations Containing Them and Their Uses
MY170719A (en) Antibody-drug conjugates
GEP201706733B (en) Anti-il-23 antibodies
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
EA201992456A3 (ru) Самостабилизирующиеся линкерные конъюгаты
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
AR088582A1 (es) Profarmaco de adrenomedulina basado en polietilenglicol y el uso del mismo
GB2492738B (en) Polyethylene glycol conjugated blood coagulation factor VIIA
SG10201507874WA (en) Molecular delivery with nanowires
CR20130021A (es) El nuevo estable polietileno glicol conjugado en interferon alfa, representado por un isómero posicional
EP2777713A4 (en) MEDICAMENTOUS CONJUGATE OF AMINO ACID-IRINOTECAN ACID POLYETHYLENE GLYCOL-OLIGOPEPTIDE AND DRUG COMPOSITION THEREOF
AU336013S (en) Oral care implement
ZA201304462B (en) Novel conjugates for targeted drug delivery
PH12015501390A1 (en) Tablets with improved acceptance and good storage stability
MY165088A (en) Pharmaceutical compositions comprising alisporivir
TR201109158A2 (tr) Eplerenon içeren kolay çözünebilen farmasötik kompozisyon.
WO2012064845A3 (en) G-csf polymer conjugates having a releasable linkage
AU328023S (en) Milk formula in tablet form
IT1406470B1 (it) Procedimento per preparare un semilavorato da mantecare e semilavorato cosi' ottenuto.
TR200900104U (tr) Çocuk muayene masası.